Genetic Basis of Primary Immunodeficiencies

Launched by NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES (NIAMS) · Nov 3, 1999

Keywords

ClinConnect Summary

The purpose of this study is to evaluate patients with primary immunodeficiency disorders to identify patients with mutations of the genes for the following proteins: Jak3, STAT1, STAT4, interleukin-7, interleukin-7 receptor, interleukin-12 receptor subunits, and others. Patients will undergo screening history, physical examination, and clinical laboratory evaluation at referring institutions and tissue samples, or cell lines will be sent to the NIH. We will establish cell lines if necessary, prepare DNA and RNA for molecular genetic analysis and study cytokine signal transduction in patien...

Gender

ALL

Eligibility criteria

• * INCLUSION CRITERIA:
• • Samples from patients with known or suspected primary immunodeficiencies, including those treated with stem cell transplants or gene correction therapy, and their families will be accepted worldwide primarily from tertiary care centers that treat patients with such immunodeficiencies.
• • Such patients will have documented evidence of either opportunistic infection, recurrent infection, or unusually severe responses to infectious agents that cause mild illness in unaffected individuals. In selected cases, at the discretion of the investigators, samples for testing will be obtained from consenting adult relatives of affected individuals.
• • Either patient-derived B cell lines or primary blood samples will be accepted although in some cases buccal swabs will also be accepted.
• • Blood samples may be obtained from unaffected children.
• • Additionally; patients with particularly interesting clinical presentations (e.g. adults with possible attenuated immunodeficiency) may be seen for outpatient visits at the NIH Clinical Center for evaluation.
• • Infants with SCID or other primary immunodeficiency will not be seen; their physicians will care them for and only clinical material will be sent on such patients.
• • Medically stable patients with mild to moderate immunodeficiency may be seen at the NIH.
• • We will encourage the participation of women and members of minority groups in this study.
• EXCLUSION CRITERIA:
• • Inability to provide informed consent.
• • A presence of any medical condition that would, in the opinion of the investigators, confuse the interpretation of the study.